飞机头痛治疗中的Rimegepant:一个案例报告
Massimo Autunno1, Marcella De Luca2, Ludovica Ferraù2
1Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. mautunno@unime.it.
Journal of medical case reports
|May 21, 2025
概括
里梅格潘特是一种与卡尔西托尼基因相关的受体对手,为飞机头痛提供了一个有前途的新疗法. 在最近的一项案例研究中,这种在飞行前服用的药物有效地控制了严重的头痛.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 飞机头痛是一种罕见的,强烈的疼痛状况,影响前额或轨道区域.
- 它可以引起严重的焦虑和飞行恐惧,尽管它的流行率很低.
- 目前的治疗策略是事,缺乏确定的指导方针.
研究的目的:
- 为了研究rimegepant治疗飞机头痛的疗效.
- 为这种特定的头痛障碍提供一种新的治疗选择.
主要方法:
- 一个28岁的女性患者的案例研究经历了反复出现的飞机头痛.
- 在飞机起飞前30分钟服用CGRP受体对抗剂rimegepant.
- 10个月的随访期,以评估治疗的有效性.
主要成果:
- 用rimegepant.成功治疗飞机头痛.
- 在10个月的随访期间,治疗的持续有效性.
- 里梅格潘特在预防和管理飞机头痛方面表现出有效性.
结论:
- 里米格培代表了对飞机头痛的一种新且有前途的治疗选择.
- 这种与calcitonin基因相关的受体对手,通常用于偏头痛,显示出飞机头痛管理的潜力.
- 这些发现表明了解决飞机头痛症状的新途径.
相关概念视频
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...


